CMS enters agreement with Vertex, bluebird to improve access to gene therapies

bluebird bio

04/12/2024 13:57

Dec 4 (Reuters) - The Centers for Medicare & Medicaid
Services on Wednesday said it had entered into agreements with
Vertex Pharmaceuticals  VRTX.O  and bluebird bio  BLUE.O  to
help increase patient access to their gene therapies.
    The so-called "outcomes-based agreements" will tie payments
to whether the therapy improves health outcomes for patients who
receive these drugs and are enrolled in government-backed
Medicaid insurance plans. 

 (Reporting by Bhanvi Satija in Bengaluru; Editing by Maju
Samuel)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))